Merit Medical Systems Inc. filings document operating and financial results, Regulation FD disclosures and material events for a medical-device manufacturer serving interventional, diagnostic and therapeutic markets. Recent Form 8-K reports cover quarterly and annual results, conference-call materials, historical revenue information under the Foundational and Therapeutic product categories, and product-related updates.
The company’s proxy materials describe board composition, governance practices, executive compensation and shareholder voting matters. Other filed event reports address board-leadership changes, completed product-technology acquisitions, capital-structure disclosure categories and clinical or regulatory disclosures tied to Merit’s device portfolio.
Merit Medical Systems (MMSI) filed its Q3 2025 10‑Q, reporting higher sales and steady profitability. Net sales were $384,157,000, up from $339,845,000 a year ago. Gross profit reached $186,411,000 versus $157,535,000. Income from operations was $42,612,000 compared with $37,261,000. Net income was $27,755,000, slightly below $28,444,000 last year. Diluted EPS was $0.46 versus $0.48.
Year to date, net sales were $1,121,970,000 vs. $1,001,356,000, and operating cash flow rose to $198,861,000 from $152,055,000. Cardiovascular segment sales were $366,425,000 in the quarter (from $322,855,000), and Endoscopy was $17,732,000 (from $16,990,000).
Cash and cash equivalents were $392,457,000, with long‑term debt of $732,916,000 related to 3.00% Convertible Notes due 2029. The company had approximately $697,000,000 in additional available borrowings under its revolver. MMSI closed the Biolife acquisition for an upfront $120,000,000 plus $7,200,000 adjustments; Biolife products contributed about $6,600,000 in net sales since closing. The effective tax rate increased to 28.0% for the quarter, reflecting legislation enacted during the period. Shares outstanding were 59,290,248 as of October 28, 2025.
Merit Medical Systems, Inc. filed a Form 8-K after issuing a press release with its operating and financial results for the quarter ended September 30, 2025. The company also held a conference call with a live webcast and slide presentation to discuss these third-quarter results and its outlook.
The press release, titled “Merit Medical Reports Third Quarter 2025 Results and Updates Full-Year Guidance,” and the conference call slides are provided as Exhibits 99.1 and 99.2. Merit highlights both GAAP and non-GAAP financial measures and states that detailed reconciliations to comparable GAAP figures are included in these materials. The company explains that it does not provide full GAAP guidance for certain metrics because it cannot reasonably predict the impact of acquisition-related items, non-cash amortization, severance, litigation, and regulatory changes on future results.
Merit Medical Systems (MMSI) announced a definitive asset purchase agreement to acquire the C2 CryoBalloon device and related technology from Pentax of America, Inc., a subsidiary of PENTAX Medical. The total purchase consideration is $22 million, including $19 million cash at closing and up to $3 million in contingent payments tied to milestones.
The closing is expected in Q4 2025, subject to satisfaction or waiver of customary closing conditions. Merit referenced non-GAAP measures in its press release and stated that a quantitative reconciliation to GAAP is not available without unreasonable effort.
Merit Medical Systems has completed a planned leadership transition, appointing Martha G. Aronson as President and Chief Executive Officer effective October 3, 2025. The Board also expanded from ten to eleven members and named her to the Board, while longtime leader Fred P. Lampropoulos moves from President and CEO to Executive Chairman through January 3, 2026 and will remain Board Chair thereafter.
Aronson’s employment terms include a $1,000,000 annual base salary, a $250,000 signing bonus, eligibility for an annual bonus targeting 100% of salary (up to 200%), and participation in the long-term equity plan with an expected initial equity award valued at $5,500,000 plus an additional $4,125,000 in performance and restricted stock units. She will also receive a $12,000 monthly transition allowance through September 30, 2026 and relocation and legal fee reimbursements. Lampropoulos retains his existing compensation through the transition period, and a separate consulting agreement with additional compensation is under negotiation.
Martha Goldberg Aronson, President and CEO and a director of Merit Medical Systems, Inc. (MMSI), reported an amended Form 4 showing a grant of 19,594 restricted stock units (RSUs) on 10/03/2025. The RSUs carry no cash purchase price and vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to her continued service; each RSU converts to one share of common stock upon vesting. The Form 4/A was signed by an attorney-in-fact on 10/07/2025.
MERIT MEDICAL SYSTEMS INC filed an amended Form 3 for insider Martha Goldberg Aronson, who serves as President, CEO, and director. This amendment is an updated initial statement of her beneficial ownership in company securities and, based on the data provided, shows no reported transactions or share movements.
Martha Goldberg Aronson, President and CEO of Merit Medical Systems, Inc. (MMSI), received a grant of 19,594 restricted stock units (RSUs) on 10/03/2025. The RSUs were granted at a reported price of $0 and represent the contingent right to receive one share of common stock per RSU upon vesting. The award vests in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service. After the grant, the reporting person is shown as beneficially owning 19,594 shares directly. The Form 4 was submitted via attorney-in-fact on 10/07/2025.
Aronson Martha Goldberg filed an Initial Statement of Beneficial Ownership (Form 3) for Merit Medical Systems Inc. The filing lists her address in South Jordan, UT and identifies her role as President and CEO. The date of the event requiring the statement is 10/03/2025.
The filing discloses no securities beneficially owned by the reporting person at the time of this Form 3. The document was signed by an attorney-in-fact, Brian G. Lloyd, on 10/07/2025.
Merit Medical Systems insider transactions: The company's President and CEO, Fred P. Lampropoulos, reported multiple stock option exercises and share surrenders on 08/29/2025. He exercised 159,151 options at a $55.73 exercise price and an additional 2,000 options at $55.73, resulting in 159,151 and 2,000 underlying shares respectively that were reported as acquired. He also surrendered 124,824 shares (for payroll taxes and option payment) and his spouse surrendered 1,454 shares for the same purpose; neither surrender involved open-market sales. Post-transactions, Mr. Lampropoulos beneficially owned 1,204,779 shares directly and certain additional shares indirectly through spouse and 401(k) holdings. Several outstanding option grants with various exercise prices and vesting schedules remain.
Lynne N. Ward, a director of Merit Medical Systems, Inc. (MMSI), executed option exercises and share sales on 08/22/2025. She exercised 3,000 non-qualified stock options with a $34.46 exercise price, resulting in 3,000 shares acquired. The same day she sold 3,000 shares in multiple transactions at a weighted average price of $88.56. After these transactions she beneficially owned 12,809 shares. The exercised options were originally granted with a $34.46 strike and become exercisable in equal annual installments of 33% commencing 08/28/2020; the exercised tranche had an expiration date of 08/28/2026.